Every fact traced to its source, and checked against it. Explore the companies, facts, and conclusions behind the news.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
In the Q3 2026 earnings season, CFOs split into two groups. Lam Research's Douglas Bettinger guides to AI-fueled semiconductor equipment demand, with a December quarter guide of $8.6B ±$400M and 2027 wafer fab equipment (WFE) demand expected to be higher. His guide is held back by supply chain limits and a falling China share. Cyclical and industrial CFOs, including Dow's Jeffrey Tate and Union Pacific's Jennifer Hamann, lean on cost self-help, layoffs, capex timing and liquidity. They are offsetting energy and fuel headwinds, a Norfolk Southern merger closing in 2H 2027, and a CFO transition at Union Pacific. Smaller names (AudioEye, Rivian, Origin Bancorp) show margin gains, executive turnover, and regulatory and financing events running into 2027. AI shows up mainly as a capex demand driver and as early agentic-adoption planning, such as Morgan Foods.
Late-2026 biotech news centers on clinical-stage companies moving assets forward. Vor Biopharma's TELIGAN Phase 3 results, Incyte's PDAC combination data at ESMO, and Akari, MapLight, Prelude and Ernexa's IND and Phase 1/2 timelines are examples. Companies are also hiring translational and business-development executives while Idorsia changes CEO. Revenue anchors are Lilly's strong weight-loss and diabetes demand, BioArctic's Leqembi royalties and VivoSim's Lilly milestones. AI-designed therapeutics (Radical Numerics' first patient treated) are a small but emerging thread.
The 2026 ESMO Congress set off a burst of oncology readouts and launches. Large and mid-cap players (Summit/Akeso with ivonescimab, Incyte in PDAC, AstraZeneca with ZEGFROVY, Astellas with CLDN18.2 real-world evidence, Abbott in MRD diagnostics) are pushing into GI cancers, targeted therapy and genomic testing. At the same time, cash-constrained small caps are cutting costs or leaving public markets (ADC Therapeutics' layoffs, Spago's Nasdaq First North delisting). Capital is concentrating in late-stage, data-backed assets and diagnostics-enabled precision oncology, while earlier-stage names face funding pressure.
Financial institutions such as East West Bank and Canara HSBC Life report solid Q3 and H1 results. Examples are fee income up 11% and Credit Life up 35%. J.P. Morgan's research is selective on aerospace and defense, keeping Overweight on Boeing and StandardAero while downgrading Leidos. Meanwhile the industry is investing in AI and resilience infrastructure: Lenovo's validated AI use cases at a European retail bank, Raiffeisen Informatik's mainframe cyber resiliency with Hitachi Vantara, and research on AI economics. All of this sits against a background of November midterm elections, input-cost pressure in industrials such as Dow, and CEO transitions.
Big pharma and life-science tooling vendors (Lilly, Thermo Fisher, Novo Nordisk) are rebuilding drug discovery around AI. NVIDIA's BioNeMo and lab-in-the-loop partnerships supply the compute and platform layer, and a wave of agent and foundation-model launches (Kala, Bionic Intelligence Research Agent, Boltz Lab, EDEN, Kosmos, OwkinZero, Natera) builds on top. Competition is shifting toward proprietary data representation, as MindWalk's HYFT patent filing shows. Novo Nordisk is also reallocating capital by closing its internal cell therapy unit and licensing the Parkinson's program to Cellular Intelligence, an AI-platform partner. The market is rewarding this posture, with Novo's stock up about 25% over 30 days after Q1 earnings.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedLandmark Deal Gives North America Its First Heavy Rare Earth Refinery
“Landmark Deal Gives North America Its First Heavy Rare Earth Refinery REAlloys, which is in the process of merging with Blackboxstocks Inc…”
Bond Traders See Tipping Point Toward New Era of Higher Yields
“Bond Traders See Tipping Point Toward New Era of Higher Yields (Bloomberg) -- A new era of elevated borrowing costs is potentially underway as war-driven inflation angst intensifies in the US bond market, sending 30-year yields toward a two-decade high above 5%…”
ING Groep’s Fed View Puts US Dollar And FX Risks In Focus
“ING Groep’s Fed View Puts US Dollar And FX Risks In Focus Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide…”
How Melbourne’s AI and Data Center Flywheel Is Accelerating Research Innovation
“IEEE Spectrum - Technical Title: How Melbourne’s AI and Data Center Flywheel Is Accelerating Research Innovation Date: 2026-05-18 10:00 Source: https://spectrum.ieee.org/melbourne-ai-data-center-innovation <img src="https://spectrum.ieee.org/media-library/hot-air-balloons-over-a-riverside-city-skyline-at-sunrise-with-p…”
14 repeat founders building agentic commerce
“CB Insights - Enterprise Ai Title: 14 repeat founders building agentic commerce Date: 2026-10-23 15:12 Source: https://www.cbinsights.com/research/14-repeat-founders-building-agentic-commerce/ <p><span style="font-weight: 400;">Some of the founders who helped build online shopping are now preparing for AI agents to do…”
NuScale Powers Up 11%, Oklo Climbs 6%, Nano Nuclear Rises 5% as the Nuclear Sector Posts Back-to-Back Rallies
“NuScale Powers Up 11%, Oklo Climbs 6%, Nano Nuclear Rises 5% as the Nuclear Sector Posts Back-to-Back Rallies Quick Read NuScale Power (SMR) stock surged today, extending a two-day rally sparked by White House space nuclear mandate…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
Third-quarter reports split into two stories: a chip-equipment maker guiding to $8.6 billion of quarterly revenue on AI spending, and chemical and rail CFOs trimming costs against fuel and energy. We checked Dow's figures against SEC filings and flag where the evidence is thin.
Robinhood's checked SEC figures show revenue up about 2.4 times in two years and a swing from loss to profit. Now it is the first retail broker to offer Cboe's company-performance contracts, while startups raise money to prove AI agents can be trusted. Some of the evidence is thin, and we say where.
Salesforce has agreed to buy Braze for about $5.66 billion, and ServiceNow has launched a credential to police AI agents. Checked SEC data shows Salesforce can afford to keep buying. Investors and vendors increasingly say that rules for AI agents, not raw capability, will decide who wins.
Analysts turned more bullish on Palantir in mid-October 2026, and the company announced several partnerships. The shares still fell 7% in one session. J.P. Morgan's defense analyst, meanwhile, downgraded Leidos. Every figure here traces to a named source.
The FDA approved a twelfth Tecentriq use, and a decision on Summit's ivonescimab is due Nov 14. Summit's SEC-filed accounts show losses and cash burn rising sharply. AstraZeneca's AI vision is, by its own telling, a forecast and not yet a result.
Palantir fell to $186.03 after a 52-week high, yet analysts upgraded or backed it and new AI partnerships arrived. J.P. Morgan's defense analyst expects solid results from traditional defense firms that may not lift their shares. Every figure here traces to a named source, and we flag where the evidence is thin.
Cancer drug makers are betting on newer treatment types, and regulators have started to approve some. Summit Therapeutics' filings show how costly that bet is: a $1.08 billion net loss in 2025 with zero revenue. The FDA rules on its lead drug on Nov. 14. The AI claims behind the story are forecasts, not results.
In one week of October 2026, Cisco, Hesai, TELUS Digital and Zeta each announced AI products at a different layer of the stack. Nvidia's checked SEC figures show its costs roughly doubling for two years. Several themes in the brief could not be verified, and we say which.
SAP and Zeta unveiled autonomous-agent platforms in the same week that Tiny bought an authorization business for about $1.9 million. The details of that sale, and one investor's warning about maths, show where the real work sits. Several sources here have mixed accuracy records, and we flag them.
A Tecentriq approval, a 14 November FDA deadline for Summit's ivonescimab and Novocure's record quarter make this a decisive stretch for cancer medicine. Summit's SEC-verified accounts show how costly the wait has been. The AI claims behind the sector's next leap come from a source our checks rate poorly.
SEC filings show Micron's capital spending rose from $8.4 billion to $15.9 billion in a year, and its cash pile has grown sharply. Alliances, custom chips and optical links are forming around the same memory and data-movement bottleneck. The Wall Street bullishness comes from a source with a weak accuracy record.
Cancer medicine is changing on three fronts at once: next-generation drugs nearing decisions, AI-designed medicines, and a take-private of a care provider. Summit Therapeutics' audited filings show what one pivotal bet has cost: $1.08 billion lost in FY2025 with no revenue.
SEC-filed numbers show Micron nearly doubled its capital spending in fiscal 2025 and now holds about $25 billion in cash. Around it, chipmakers are locking in supply and merging. Several of the sources behind those deals have mixed accuracy records, and we show that below.
A cluster of cancer-drug milestones lands this autumn. One, a Phase 3 myeloma readout, has already reported a 51% cut in progression risk. Two more are dated: ESMO on Oct 24 and an FDA decision on Nov 14. We checked Merck's SEC-filed figures and weighed how reliable each source is.
Two dated events will test oncology's new tools within weeks: Merck and Moderna's personalized mRNA vaccine data at ESMO on Oct. 24, and the FDA decision on Summit's ivonescimab on Nov. 14. We checked Merck's SEC-filed numbers and flag where the sources are weak.
SEC-filed figures show Micron's capital spending roughly doubled in fiscal 2025 and its cash pile has since more than doubled in a year. Analysts back the AI-infrastructure names while flagging a 171x sales multiple at D-Wave and a split consumer. We also show how reliable each source is.
SEC filings show Micron's capital spending nearly doubled in fiscal 2025 and its cash pile has grown to about $25 billion. Analysts expect the AI chip shortage to last 12 to 18 months. We checked the numbers against filings and flagged where the analyst claims rest on weaker sources.
A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only part of company data. Money is moving to governance and data plumbing. We checked the figures, and the survey piece itself scores poorly on source reliability.
Several well-known companies announced new chief executives or CEO searches between July and early October 2026. Via News checked each against its source. The handoffs are mostly orderly, but one departure was abrupt, one company is still searching, and the sources' accuracy records vary widely.
Meta's new enterprise platform will be led by MongoDB's departing CEO, while small AI-native startups raise funding. Investors say back-office finance software is next, but one of them warns AI is bad at maths. We flag which sources are weaker and which parts of the story our evidence cannot yet support.
A survey says 100% of organizations plan to use AI agents within two years, yet only about 45% of company data is AI-accessible. We checked the claims against sources, and the survey's publisher scored poorly on reliability, so we flag that. Nvidia's SEC-verified costs show the build-out is real.
A personalised mRNA vaccine from Merck and Moderna stopped melanoma returning in a trial, and AstraZeneca is betting AI can speed up drug design. Via News checked what the record supports: some of the optimism rests on firm data, and some on sources that failed our own reliability tests.
Verified SEC figures show Nvidia's cost of revenue rose about 3.8 times in two fiscal years. A survey says every respondent plans to use AI agents, but company data and trust lag. That survey's source failed our check on all 11 claims we tested, so we flag it and lean on the data that held.
SEC-filed figures show Micron nearly doubled its capital spending in fiscal 2025 and now holds about 2.5 times the cash it had a year earlier. Analyst enthusiasm for power, data-center and quantum stocks rests on sources that held up only about half the time in our checks.
Companies from Manulife to Box customers are rolling out AI agents, and funding is flowing. But a trade-press study reports that in 'data laggard' firms, AI can reach 30% or less of company data. That source has a poor measured record, so we flag it as a claim, not a fact.
Every company surveyed by MIT Technology Review plans to use AI agents within two years, yet firms with weak data give those agents access to 30% or less of it. Only some of this is firmly established: that survey's source scores 0% on our reliability check, and the Nvidia figures are SEC-verified.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.